EVMN

Evommune, Inc.

Healthcare
Biotechnology
$241M market cap

Forecast run · Nov 10, 2026Upside rank 199 of 3,179

Model Signal

ForecastQ Daily Probabilities

65.2%

60.8%

72.5%

Analyst Consensus

Recommendation2.40/5 Buy

Last price$6.65

Price target$25.00

Implied move+275.9%

Analysts5

ForecastQ Portfolios

EVMN is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.